XML 47 R31.htm IDEA: XBRL DOCUMENT v3.6.0.2

Collaborative Research, Development and License Agreements (Tables)

12 Months Ended

Dec. 31, 2016

Astra Zeneca

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues earned under our agreement with AstraZeneca, included as collaboration revenue in our consolidated statements of operations (in thousands):

		Year ended December 31,
		2016				2015				2014
Initial and milestone payment		$	7,722			$	238			$	681
Subsequent payment			1,953				892				2,554
Performance of research activities			103				1,635				2,174
Total		$	9,778			$	2,765			$	5,409

X

- Definition

Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68059916&loc=d3e50766-111635

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68059916&loc=SL6750900-111635

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: